Brivudine: potentially fatal toxicity of fluoropyrimidines if administered shortly before or at the same time with brivudine or used within 4 weeks after the end of treatment with brivudine
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Active substance |
Brivudine
|
| Procedure number |
PSUSA/00000434/201907
|
| Regulatory outcome |
Variation
|
| DHPC type |
Periodic safety update single assessment
|
| Human ATC code |
J05AB15
|
| Dissemination date |
12/05/2020
|